CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨*

doi:10.3969/j.issn.1672-5069.2022.03.020

Abstract

Abstract: Objective The aim of this study was to explore the implication of hepatic fat fraction (HFF) by CT angiography (CTA) in patients with nonalcoholic Fatty liver diseases (NAFLD) and high-risk coronary plaque (HRP). Methods 168 patients with NAFLD were admitted to our hospital between January 2015 and January 2021, and all underwent CTA check-up. The HFF was automatically given atSyngo.via station. Results Out of the 168 patients with NAFLD, there were no coronary plaque in 76 cases, with coronary plaque but not risk in 48 cases and with HRP in 44 cases; the epicardial adipose tissue volume (EATV) in plaque-free, HRP negative and HRP group were 91.8(82.4, 98.3)cm³, 102.6(87.6, 120.4)cm³ and 136.2(82.4, 98.3)cm³, significantly statistically different (P < 0.05); the CT values of EAT in the three groups were -79.3(-81.2, -76.4) HU, -74.2(-77.3, -70.4)HU and -66.8(-70.5, -63.4) HU, significantly different (P < 0.05); the CT values of pericoronary adipose tissue (PAT) were -79.0(-80.6, -76.3)HU, -73.1(-75.2, -70.2)HU and -66.2(-70.1, -63.0)HU, significantly different (P < 0.05); the PAT volume (PATV) were [17.5(15.5, 18.6)cm³], [17.4(15.7, 21.8)cm³] and [18.9(17.5, 23.1)cm³], significantly different(P<0.05) among the three groups; the HFF were [6.8(5.3, 9.2)%], [8.8(7.0, 12.6)%] and [15.4(12.3, 17.8)%], significantly different(P<0.05); the CT value of liver were [(44.4±4.7)HU], [(43.2±4.6)HU] and [(39.7±4.4)HU], significantly different(P<0.05); there were significant differences in smoking habit, blood hypertension, diabetes, neutrophil/lymphocyte ratio (NLR), HDL, TG, TC and Framingham risk score among the three groups(P<0.05); there were significant differences in coronary artery stenosis degree, low density plaque, punctate calcified plaque, remodeling index and napkin ring sign between patients with HRP negative and with HRP (P<0.05). Conclusion As a new non-invasive imaging marker for liver fat measurement, the HFF has the advantages of simple measurement and good repeatability, which might help optimize the cardiovascular risk stratification in patients with NAFLD.

Key words: Nonalcoholic fatty liver diseases, High-risk coronary plaque, CT angiography, Liver fat fraction

Cai Dongmei, Wu Wenjuan, Jiang Yilun, et al. Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque[J]. Journal of Practical Hepatology, 2022, 25(3): 383-386.

References

[1] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019, 69(6):2672-2682.
[2] Zhou JH, Cai JJ, She ZG, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol, 2019, 25(11):1307-1326.
[3] Ferrara D, Montecucco F, Dallegri F, et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol, 2019, 234(12):21630-641.
[4] Kovalic AJ, Satapathy SK. The role of nonalcoholic fatty liver disease on cardiovascular manifestations and outcomes. Clin Liver Dis, 2018, 22(1):141-174.
[5] Osawa K,Miyoshi T, Yamauchi K, et al. Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT. PLoS One, 2015, 10(6):e0131138.
[6] Park HE, Lee H, Choi SY, et al. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol, 2019, 54(3):271-280.
[7] Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol, 2019, 7(9):715-725.
[8] Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015, 274(3):693-701.
[9] Hur BY, Lee JM, Hyunsik W, et al. Quantification of the fat fraction in the liver using dual-energy computed tomography and multimaterial decomposition. J Comput Assist Tomogr, 2014, 38(6):845-852.
[10] Hyodo T, Yada N, Hori M, et al. Multimaterial decomposition algorithm for the quantification of liver fat content by using fast-kilovolt-peak switching dual-energy CT: clinical evaluation. Radiology, 2017, 283(1):108-118.
[11] Hyodo T, Hori M, Lamb P, et al. Multimaterial decomposition algorithm for the quantification of liver fat content by using fast-kilovolt-peak switching dual-energy CT: experimental validation. Radiology, 2017, 282(2):381-389.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2010, 18(3):163-166.
[13] Kolossváry M, Szilveszter B, Merkely B, et al. Plaque imaging with CT-a comprehensive review on coronary CT angiography based risk assessment. Cardiovasc Diagn Ther, 2017, 7(5):489-506.
[14] Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA, 2008, 300(2):197-208.
[15] Meng X, Wang W, Zhang K, et al. Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population. Ther Clin Risk Manag, 2018, 14:1499-1506.
[16] Fracanzani AL, Pisano G, Consonni D, et al. Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease. PLoS One, 2016, 11(9):e0162473.
[17] Park HE, Kwak MS, Kim D, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab, 2016, 101(8):3134-3143.
[18] Mendonca PR, Lamb P, Sahani DV. A flexible method for multimaterial decomposition of dual-energy CT images. IEEE Trans Med Imaging, 2014, 33(1):99-116.
[19] Kuschnerus K, Landmesser U, Kránkel N. Vascular repair strategies in type 2 diabetes: novel insights. Cardiovasc Diagn Ther, 2015, 5(5):374-386

Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[2]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[3]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[4]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[5]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[6]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[7]	Liu Xiangji, Liu Zhenxian, Wang Xiaoyan. Incidence of gallstone disease in middle-aged and elderly patients with nonalcoholic fatty liver disease and its relation to metabolic risk factors [J]. Journal of Practical Hepatology, 2021, 24(3): 363-366.
[8]	Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage [J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.
[9]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[10]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[11]	Li Pingying, Li Juan, Xie Shouzhen, et al. Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions [J]. Journal of Practical Hepatology, 2020, 23(6): 817-820.
[12]	Fang Yi, Chen Yixiong, Pei Dongping, et al.. Short-term efficacy of entecavir and lactobacillus acidophilus compound combination in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(5): 634-637.
[13]	Tang Xiaofei, Zhong Mengju, Shen Haijuan. Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats [J]. Journal of Practical Hepatology, 2020, 23(3): 328-331.
[14]	Tang Xinya,Hou Sen,Jiao Yingying. Effect of captopril on steatosis of hepatocytes in rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(3): 332-335.
[15]	Shen Jingyong, Guo Xiangyun, Zhou Hui, et al. Effect of radical therapy forHelicobacter pylori on serum inflammatory factors and lipid metabolism in patients with Hp positive non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 364-367.